In summary, our pre-clinical studies support SMO as a therapeutic target in melanoma and offer insights into the clinical potential of this new treatment strategy both as a single agent and in combination with other targeted agents in metastatic melanoma patients. Here, SMO is linked to metastatic melanoma.